NCT05062486View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of RQC for AMD

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

October 4, 2021

Primary Completion Date

November 7, 2024

Study Completion Date

November 7, 2024

Conditions
Age-related Macular Degeneration
Interventions
DRUG

Resveratrol, Quercetin, Curcumin (RQC)

100 mg resveratrol, 120 mg quercetin, 1000 mg curcumin BID

DRUG

Curcumin

1000 mg curcumin BID

Trial Locations (1)

60611

Zaparackas M.D. & Knepper M.D. Ph.D., Ltd, Chicago

All Listed Sponsors
lead

Paul A Knepper, MD PhD

OTHER

NCT05062486 - A Study to Evaluate the Safety and Efficacy of RQC for AMD | Biotech Hunter | Biotech Hunter